Latest News about FDA
Recent news which mentions FDA
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate
September 23, 2024
From Benzinga
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
September 23, 2024
From Benzinga
ICU Medical Recalls ParaPAC Plus Ventilators Due To Loose Outlet Connector That Can Cause Injury Or Death
September 20, 2024
From Benzinga
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
September 20, 2024
From Benzinga
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
September 20, 2024
From Benzinga
Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy
September 20, 2024
From Benzinga
ICU Medical Recalls Certain Tracheostomy Tubes Due To Manufacturing Defects
September 19, 2024
From Benzinga
FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies
September 19, 2024
From Benzinga
Zimmer Biomet To Stop Selling CPT Hip Implant System By End Of 2024 Due To High Fracture Risks
September 18, 2024
From Benzinga
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
September 18, 2024
From Benzinga
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
September 18, 2024
From Benzinga
Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug
September 18, 2024
From Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
September 18, 2024
From Benzinga
Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss
September 16, 2024
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.